[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352637-105":59,"doc-detail-352637-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","metabolic-dysfunction-associated-steatotic-liver-disease-masld-and-risk-of-gynecologic-cancer-a-nationwide-cohort-study","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer - A Nationwide Cohort Study","","Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multisystem disorder with oncogenic implications beyond liver-specific outcomes, yet its relationship with gynecologic cancers remains insufficiently defined in large population studies. Methods: A longitudinal nationwide Korean cohort of over 2 million women with median 12.3 years follow-up was analyzed; MASLD subtypes were identified using recent diagnostic standards, and Cox models estimated adjusted hazard ratios accounting for metabolic, reproductive, and lifestyle factors. Results: MASLD increased cervical, endometrial, and ovarian cancer risks in both premenopausal and postmenopausal women. Conclusions: MASLD is an independent, modifiable risk factor, supporting liver-health assessment in gynecologic cancer prevention and screening.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/metabolic-dysfunction-associated-steatotic-liver-disease-masld-and-risk-of-gynecologic-cancer-a-nationwide-cohort-study/352637/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/metabolic-dysfunction-associated-steatotic-liver-disease-masld-and-risk-of-gynecologic-cancer-a-nationwide-cohort-study/352637.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this nationwide cohort study?","Question",{"text":113,"@type":114},"To evaluate whether metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with an increased risk of gynecologic cancers in a large Korean population.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was MASLD defined in the study?",{"text":118,"@type":114},"MASLD and its subtypes, including metabolic alcohol-associated liver disease (MetALD) and alcohol-related liver disease (ALD) with metabolic dysfunction, were identified using the most recent diagnostic standards.",{"name":120,"@type":111,"acceptedAnswer":121},"Does the study find the association between MASLD and cancer risk in both menopausal groups?",{"text":122,"@type":114},"Yes. MASLD was associated with higher risks of cervical, endometrial, and ovarian cancers in both premenopausal and postmenopausal women.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352637,1790168008,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer: A Nationwide Cohort Study  \nMin Jin Jeong 1, Yong Seok Lee 1, Youn Jin Choi 2, *,† and Kyung Do Han 3, *,†  \nAcademic Editor: Duke Appiah  \nReceived: 9 January 2026  \nRevised: 5 March 2026  \nAccepted: 9 March 2026  \nPublished: 10 March 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Obstetrics and Gynecology, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 03312, Republic of Korea; [mjobgy@catholic.ac.kr](mjobgy@catholic.ac.kr) (M.J.J.)  \n2 Department of Obstetrics and Gynecology, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seochogu, Seoul 06591, Republic of Korea  \n3 Department of Statistics and Actuarial Science, Soongsil University, Seoul 06978, Republic of Korea  \n* [Correspondence: yunno@catholic.ac.kr](Correspondence: yunno@catholic.ac.kr) (Y.J.C.); [hkd917@naver.com](hkd917@naver.com) (K.D.H.)† These authors are co-corresponding authors.  \nSimple Summary  \nMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic condition that influences cancer development beyond the liver. While its impact on various metabolic disorders is well-documented, the specific relationship between MASLD and gynecologic cancers has not been fully explored in large-scale populations. In this study, we demonstrated that MASLD significantly increases the risk of cervical, endometrial, and ovarian cancers regardless of menopausal status, using a comprehensive nationwide database of over 2 million individuals. Our findings suggest that MASLD serves as a critical, modifiable risk factor for gynecologic malignancies. Consequently, integrating liver health assessments into routine gynecologic cancer screening could provide a proactive strategy for early prevention and risk management in women with metabolic dysfunction.  \nAbstract  \nBackground: Metabolic dysfunction-associated steatotic liver disease (MASLD) is now widely identified as a multisystem disorder with oncogenic implications that extend beyond liver-specific outcomes. Nonetheless, the link between MASLD and gynecologic cancers remains insufficiently characterized in robust, well-powered population studies. We investigated this association by menopausal status in a large cohort of Korean women. Methods: We performed a longitudinal cohort study utilizing data from a nationwide Korean cohort of over 2 million women, with a median observation period of 12.3 years. MASLD, including its subtypes metabolic alcohol-associated liver disease (MetALD), and alcohol-related liver disease (ALD) with metabolic dysfunction were identified using the most recent diagnostic standards. Adjusted hazard ratios (aHR) for gynecologic cancers were estimated with Cox models, accounting for metabolic, reproductive, and lifestyle factors. Results: In premenopausal women, MASLD was associated with increased risks of cervical (aHR, 1.13, 95% CI, 1.01–1.26), endometrial (aHR, 1.63, 95% CI, 1.50–1.79) and ovarian cancer (aHR, 1.22, 95% CI, 1.12–1.33) . In postmenopausal women, MASLD similarly conferred elevated risks across all three cancers: cervical (aHR, 1.12, 95% CI, 1.05–1.20), endometrial (aHR, 1.42, 95% CI, 1.32–1.54) and ovarian cancer (aHR, 1.14, 95% CI, 1.08–1.20) . Conclusions: MASLD should be considered an independent and modifiable risk determinant for gynecologic cancers. These data underscore the necessity of including hepatic steatosis in risk assessment protocols for cancer prevention. Early recognition and directed  \nscreening among metabolically susceptible women may provide important avenues for proactive cancer risk reduction.  \nKeywords: metabolic dysfunction-associated steatotic liver disease;","cbCaipk4dXYpApDp","https://ap.wps.com/l/cbCaipk4dXYpApDp","pdf",933752,18,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"What is the main purpose of this nationwide cohort study?\",\"answer\":\"To evaluate whether metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with an increased risk of gynecologic cancers in a large Korean population.\"},{\"question\":\"How was MASLD defined in the study?\",\"answer\":\"MASLD and its subtypes, including metabolic alcohol-associated liver disease (MetALD) and alcohol-related liver disease (ALD) with metabolic dysfunction, were identified using the most recent diagnostic standards.\"},{\"question\":\"Does the study find the association between MASLD and cancer risk in both menopausal groups?\",\"answer\":\"Yes. MASLD was associated with higher risks of cervical, endometrial, and ovarian cancers in both premenopausal and postmenopausal women.\"}]","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Risk of Gynecologic Cancer - A Nationwide Cohort Study | PDF",1790100571,45]